T790M (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "T790M" in French language version.

refsWebsite

Global rank French rank

2^nd place

3^rd place

4^th place

12^th place

57^th place

4^th place

low place

447^th place

1,409^th place

doi.org

Tan CS, Gilligan D, Pacey S, « Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer », Lancet Oncol., vol. 16, n^o 9,‎ 2015, e447–59 (PMID 26370354, DOI 10.1016/S1470-2045(15)00246-6)
Kazuya Ofuji, Yoshitaka Tada, Toshiaki Yoshikawa et Manami Shimomura, « A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer », International Journal of Oncology, vol. 46, n^o 2,‎ février 2015, p. 497–504 (ISSN 1019-6439, DOI 10.3892/ijo.2014.2787, lire en ligne, consulté le 14 octobre 2017)
Remon J, Planchard D, « AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients », Future Oncol, vol. 11, n^o 22,‎ 2015, p. 3069–81 (PMID 26450446, DOI 10.2217/fon.15.250)
« Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors », Clin Cancer Res, vol. 12, n^o 1,‎ 2006, p. 6494–501 (PMID 17085664, DOI 10.1158/1078-0432.CCR-06-1570)
Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H, « Emerging treatment for advanced lung cancer with EGFR mutation », Expert Opin Emerg Drugs, vol. 20,‎ 2015, p. 1–16 (PMID 26153235, DOI 10.1517/14728214.2015.1058778)

U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. [1]

Kazuya Ofuji, Yoshitaka Tada, Toshiaki Yoshikawa et Manami Shimomura, « A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer », International Journal of Oncology, vol. 46, n^o 2,‎ février 2015, p. 497–504 (ISSN 1019-6439, DOI 10.3892/ijo.2014.2787, lire en ligne, consulté le 14 octobre 2017)

Tan CS, Gilligan D, Pacey S, « Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer », Lancet Oncol., vol. 16, n^o 9,‎ 2015, e447–59 (PMID 26370354, DOI 10.1016/S1470-2045(15)00246-6)
Remon J, Planchard D, « AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients », Future Oncol, vol. 11, n^o 22,‎ 2015, p. 3069–81 (PMID 26450446, DOI 10.2217/fon.15.250)
« Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors », Clin Cancer Res, vol. 12, n^o 1,‎ 2006, p. 6494–501 (PMID 17085664, DOI 10.1158/1078-0432.CCR-06-1570)
Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H, « Emerging treatment for advanced lung cancer with EGFR mutation », Expert Opin Emerg Drugs, vol. 20,‎ 2015, p. 1–16 (PMID 26153235, DOI 10.1517/14728214.2015.1058778)

Kazuya Ofuji, Yoshitaka Tada, Toshiaki Yoshikawa et Manami Shimomura, « A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer », International Journal of Oncology, vol. 46, n^o 2,‎ février 2015, p. 497–504 (ISSN 1019-6439, DOI 10.3892/ijo.2014.2787, lire en ligne, consulté le 14 octobre 2017)